Access Update - #13

After months of research, I’m pleased to announce our second recommendation:

“Buy” Cytori Therapeutics(Nasdaq: CYTX) up to $8.

Cytori Therapeutics is the maker of a device that removes stem cells from a patient’s own fat cells. Those stem cells are then reintroduced into the body. Currently, the device is being used in Europe and Asia for breast reconstruction after partial mastectomy. However, indications are that, although the device was just made available in the first quarter, physicians are already expanding its use for full mastectomies and even cosmetic augmentation.

Cytori has another product commercially available in Japan called StemSource Cell Bank. Patients can cryopreserve their own stem cells for future use. Additionally, the company is in clinical trials for heart disease.

You can view the full report here. http://www.mtvernonresearch.com/bin/q/j/cytx.pdf . You can also view the report by visiting our website www.mtvernonresearch.com and clicking on Access Research Group on the upper right hand side of the page.

As mentioned in previous updates, we will host a private conference call for Access subscribers and Cytori’s management. On the call will be Cytori CEO Chris Calhoun, CFO Mark Saad and President and Dr. Marc Hedrick. Dr. Michael Scheflan, Plastic Surgeon and Director of the Atidim Medical Center in Tel Aviv, Israel will join us as well.

The call will take place on Wednesday, May 28 at 12:30 p.m. ET/9:30 a.m. PT . There will be an online PowerPoint presentation to go along with the call. If you are not available for the live call, both the audio portion as well as the PowerPoint presentation will be archived on our website approximately two days after the live event.

You will receive an e-mail this weekend with information on how to access the call and presentation.

During the conference call we will ask the speakers as many of your questions as we can. Please read the report and then e-mail your questions to research@accessresearchgroup.com .

I am very excited about this company. Cytori is out in front of a revolutionary technology and has the opportunity to be a leader in a game-changing area of medicine.

Marc Lichtenfeld
Director of Research
Access Research Group

Stock
Symbol
Current Price
Comments

Electro-Optical Sciences

MELA

$7.27

Buy up to $5.75

Cytori Therapeutics

CYTX

$6.06

Buy up to $8